
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cystinosin CRISPR/Cas9 KO Plasmid (m) | sc-429900 | 20 µg | $397.00 |
Ctns encodes cystinosin, a lysosomal H+-driven cystine transporter that mediates cystine efflux from the lysosomal lumen to the cytosol, linking lysosomal transport to cellular redox balance and amino acid homeostasis. Loss of cystinosin activity perturbs lysosomal function, promotes cystine accumulation, and alters pathways involved in autophagy–lysosome dynamics, oxidative stress responses, and metabolic adaptation. In mouse systems, Ctns disruption is widely used to model mechanisms underlying cystine storage phenotypes and to examine how lysosomal transport defects reshape cellular stress signaling. These processes are relevant to understanding how lysosome-centered trafficking and degradation networks influence tissue homeostasis in renal, ocular, and immune-relevant cell types.
Cystinosin CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ctns gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ctns together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ctns open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Cystinosin protein expression.
This CRISPR knockout system enables efficient generation of Ctns-deficient cell models for investigation of Cystinosin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.